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of lead on putative OA biomarkers. We examined whole blood Pb
levels and OA biomarkers in African American and white women.
Methods: A total of 339 women in the Johnston County OA
Project Metals Exposure Sub-study (mean age 62.5 (9.4) years,
35% African American) had available whole blood, serum, or
urine samples for whole blood lead and biomarkers assessments.
Whole blood lead was measured by inductively coupled plasma
mass spectrometry at the Inorganic Toxicology laboratory, Divi-
sion of Laboratory Sciences, National Center for Environmental
Health, CDC, Atlanta, Georgia. Urine C-telopeptide fragments
of type II collagen (CTX-II), cross linked N telopeptide of type
I collagen (NTX-I), serum hyaluronic acid (HA) and cartilage
oligometric matrix protein (COMP) were measured by commer-
cially available kits. Radiographic knee OA (rKOA) was defined
by Kellgren-Lawrence grades (2-4) with fixed-flexion posterior-
anterior knee films. Pearson correlation coefficients were calcu-
lated between Log Pb and log of each biomarker. Analysis of
covariance models were used to examine associations between
blood lead levels and the 4 chosen biomarkers with log trans-
formed biomarkers as outcomes, adjusted for age, race, BMI,
and rKOA variables. Effect modification between log Pb and race
were examined, with significance defined by p-values < 0.1 for
interaction terms.
Results: Median Pb levels were 1.9 ug/dL (0.5-25.4) and were
higher in African American women than white women (p <
0.001). In bivariate associations, log Pb was correlated with log
CTX-II (r=0.14, p=0.009) and log NTX-I (r=0.22, p<0.0001), but
not with log COMP or log HA (r= 0.07 and 0.06, respectively,
p>0.20). In adjusted models, log Pb was associated with mean
log CTX-II (p = 0.007), NTX-I (p <0.001), and COMP (p = 0.036),
but not with mean log HA (p = 0.9). There were no notable race
and log Pb interactions.
Conclusions: Mean blood Pb levels are associated with urine
CTX-II, urine NTX-I, and serum COMP, but not serum HA in both
African American and white women. These data suggest that
Pb has an effect not only on bone collagen, but also on type II
collagen and non-collagenous matrix proteins. Potential effects
of Pb in the pathogenesis of OA, then, are likely to be related
to alterations in these factors, but not to effects on synovial
inflammation. We are planning further studies to delineate how
Pb may affect joint structures and how other factors such as
menopause, hormone replacement therapy, and bone density,
might influence these associations.
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Purpose: Data from a meta-analysis of randomized controlled
trials suggest that 1 g of naproxen is not associated with dele-
P96 – Table 1. Percent Inhibition of Serum Thromboxane (TXB2) trough/steady state*
Period 1 Period 2 (EC-ASA 81mg) Period 1 - Period 2 Lower Limit Non-inferiority (5%)
Mean (SD) Mean (SD) Mean Difference(SD) One-sided 95% CI
NAPSO 220 mg bid (440 mg) (n=11) 97.9 (3.20) 98.4 (2.54) -0.5 (2.20) -1.7
NAPSO220 mg tid (660 mg) (n=9) 99.4 (0.77) 98.0 (2.57) 1.3 (2.46) -0.2
NAPSO550 mg bid (1100 mg) (n=11) 99.6 (0.69) 97.2 (5.65) 2.3 (5.46) -0.6
Placebo (n=10) 47.3 (41.03) 99.2 (1.01) -51.9 (41.18) -75.8
*Blood drawn 24 hrs after last ASA dose and 12 hrs after last NAPSO dose at steady state
terious cardiovascular outcomes, perhaps due to its antiplatelet
effects. The effect of over-the-counter (OTC) doses of naproxen
on platelets is unknown. We compared the antiplatelet effects
of OTC doses of naproxen sodium (NAPSO) with a prescrip-
tion (Rx) dose of NAPSO and low-dose enteric-coated aspirin
(EC-ASA).
Methods: Single-center, randomized, open-label, placebo-
controlled, 2-period crossover trial in healthy male and female
subjects. Subjects were administered 1 of 3 regimens of NAPSO
(NAPSO 220 mg twice daily (bid), NAPSO 220 mg 3 times daily
(tid), or NAPSO 550 mg bid) or placebo for 7 days. After a
washout period of at least 6 days, subjects were crossed over
to receive EC-ASA 81 mg once daily for 7 days. The primary
endpoint was inhibition of serum thromboxane B2 (TXB2), mea-
sured at trough (12 hours after the final dose of NAPSO) and 24
hours after final dose of EC-ASA. Inhibition of serum TXB2 was
measured by a commercially available enzyme immunoassay.
Results: A total of 48 subjects were randomized [the intent-
to-treat (ITT) population], and 41 (11 NAPSO 220 mg bid, 9
NAPSO 220 mg tid, 11 NAPSO 550 mg bid, 10 placebo) met
the criteria for the evaluable population. Baseline characteristics
were comparable among the 4 groups. NAPSO demonstrated
an aspirin-like effect on platelet aggregation, as measured by
inhibition of serum TXB2. The mean (±SD) degree of serum
TXB2 inhibition was 97.9% (± 3.20%) for NAPSO 220 mg bid
and 99.4% (± 0.77%) for NAPSO 220 mg tid. The inhibitory
effects of these OTC doses of NAPSO were similar to the Rx
dose of NAPSO 550 mg bid [99.6% (± 0.69%)]. The lower limit
of a one-sided 95% CI test for non-inferiority (NAPSO or placebo
versus ASA) for each treatment was -1.7% for NAPSO 220 mg
bid, -0.2% for NAPSO 220 mg tid, -0.6% for NAPSO 550 mg bid,
and -75.8% for placebo (Table 1). All doses of NAPSO were not
inferior to EC-ASA 81 mg. Results were confirmed in an analysis
of the ITT population.
Conclusions: Over-the-counter doses of NAPSO produced an
antiplatelet effect similar to low dose EC-ASA and Rx dose
NAPSO, as measured by inhibition of serum TXB2.
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Purpose: Inter-α-trypsin Inhibitor (IαI) occurs in plasma and
has protease inhibitory activity. Heavy chains of IαI can bind
covalently to hyaluronan (HA) to form a serum derived hyaluro-
nan associated protein, SHAP, releasing bikunin. The transfer
of IαI heavy chain to HA is catalyzed by enzyme factors such
as TNFα-stimulated gene 6 protein (TSG-6). SHAP potentiates
CD44-mediated leukocyte adhesion to hyaluronan substratum,
and has putative roles in HA cross-linking and inflammation.
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P97 – Table 1. Concentrations in SF and serum of SHAP, HA, IL-8 and MMP-3. Values are median (25th-75th percentiles)
REF PPA INJ POA
SHAP serumng/mL 7.2 (6.5-9.5) 15.0 (9.3-26.5) 11.5 (8.7-15.6) 10.5 (8.0-13.6)
SHAP SFng/mL 3243 (1723-5965) 37031 (17163-56600) 6211 (2939-14442) 10910 (2415-20045)
HA serumng/mL 47 (31-61) 32 (29-61) 36 (28-48) 39 (28-44)
HA SFμg/mL 1515 (1442-2327) 500 (325-719) 1604 (672-2891) 2539 (1309-5741)
IL-8 serumpg/mL 11.2 (8.7-31.8) 289 (48.2-6062) 26.3 (5.9-193) 25.2 (5.3-217)
IL-8 SFpg/mL 2.1 (0.1-14.4) 26.9 (24.0-140) 2.6 (0.48-15.6) 2.8 (0.04-14.4)
MMP-3 SFng/mL 808 (776-1315) 12430 (3427-52195) 1298 (423-3640) 3355 (1133-12760)
MMP-3 serumng/mL 28 (22-77) 61 (33-143) 33 (22-44) 50 (30-88)
The CXC chemokine interleukin 8 (IL-8), a potent neutrophil
recruiting and activating factor, is a pro-inflammatory cytokine
present in many disease conditions. Matrix metalloproteinase-3
(MMP-3) synthesis and secretion in chondrocytes and synovial
cells is upregulated by inflammation. We determined levels of
SHAP, HA, IL-8 and MMP-3 in synovial fluid (SF) and serum
from patients with OA, inflammatory arthritis and joint injury.
Methods: Paired knee SF and serum samples were from a con-
venience sample of patients with primary knee OA (POA n=43,
mean age 49), knee injury (INJ n=212, mean age 34), pseu-
dogout (PPA n=10, mean age 38), and knee-healthy persons
(n=8, mean age 30). SHAP and HA were quantified by ELISAs,
using plates coated with HA-binding region of bovine aggrecan.
MMP-3 protein was assayed by ELISA. IL-8 was quantified by
LINCO human cytokine multiplex kit (HCYTO-60K-PMX22, and
HCYTO-60K-PMX21).
Results: Group median levels of SHAP in SF were 500-2500
times higher than those in serum, with overall levels highest in
pseudogout (p<0.001, Table 1). The amount of SHAP relative
Fig. 1
Fig. 2
to HA was higher in serum than in SF. SHAP levels in SF
were highly correlated with MMP-3 protein (R=0.7, p<0.001, Fig.
1). IL-8 levels correlated with SHAP (R=0.44, p<0.001, Fig. 2)
and MMP-3 (R=0.40, p<0.001). HA levels in SF were low in
pseudogout, normal or high in OA. SHAP concentrations in SF
were elevated for 3 months after knee injuries that commonly
lead to OA, while HA levels were low (p<0.005).
Conclusions: We find very high concentrations of SHAP in
synovial fluid, suggesting local production in the joint. Concen-
trations of SHAP in joint fluid were highly correlated with MMP-3
and IL-8, suggesting synovial activation in joint injury and OA,
as well as in arthritis. In contrast to some previous reports, HA
levels in OA joints were normal or high, compared to those in
healthy knee joints. The observed changes of these potential
biomarkers are consistent with an upregulation of inflammation
after joint injury and in OA.
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Purpose: Concentration, isomer composition, and immunoreac-
tivity of glycosaminoglycans (GAGs), such as chondroitin sulfate
(CS) have been widely studied as biomarkers to monitor changes
in the metabolism of joints. We have shown previously, by se-
quential use of gel filtration chromatography (Superose 6) and
fluorophore-assisted carbohydrate electrophoresis (FACE), that
CS chains in synovial fluid of injured joints are significantly longer
than those in normal joints. FACE is a technique that requires
specialized laboratory equipment and a high level of technical
expertise. Additionally, FACE technique is much more expen-
sive in terms of materials and time per sample. The aim of the
present study was to determine whether dimethylmethylene blue
(DMMB) analysis could be done instead of FACE to determine
CS chain length in synovial fluid.
Methods: Synovial fluid was obtained from carpal joints of: (1)
8 normal Thoroughbred horses after 8 weeks rest, (2) the same
horses after 9 months treadmill training, and (3) 7 Thoroughbred
horses with osteochondral (OC) injury from racing. Superose 6
chromatography and FACE analysis had previously been per-
formed on these samples. Aliquots (250 ul) of the same synovial
fluids were digested in proteinase K, filtered, and then eluted
on a Superose 6 column. Column effluent was collected in 1
ml fractions. Fractions 1 through 13 were discarded; fractions
14 through 23 were collected and analyzed. Our previous work
has shown that the sulfated GAG contained in these fractions is
chondroitin sulfate. DMMB was performed by modification of the
Blyscan method (Biocolor, Accurate Chemical Supplies, West-
bury, NY), adapted to a 384-well microplate technique. Data from
each fraction of each sample was compared between the 2 as-
say methods by Wilcoxon matched-pairs signed-ranks test, with
P>0.05 considered significant.
Results: Sulfated GAG from synovial fluid was quantitated in
ug/ml of fluid by DMMB, according to fragment size. Figure 1A
